Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer - PubMed (original) (raw)
Clinical Trial
doi: 10.1200/JCO.2000.18.1.136.
B Perpoint, R Zidani, N Le Bail, R Faggiuolo, C Focan, P Chollet, J F Llory, Y Letourneau, B Coudert, F Bertheaut-Cvitkovic, D Larregain-Fournier, A Le Rol, S Walter, R Adam, J L Misset, F Lévi
Affiliations
- PMID: 10623704
- DOI: 10.1200/JCO.2000.18.1.136
Clinical Trial
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti et al. J Clin Oncol. 2000 Jan.
Abstract
Purpose: To study how adding oxaliplatin (l-OHP) to chronomodulated fluorouracil (5-FU)-leucovorin (LV) affected the objective response rate, as first-line treatment of metastatic colorectal cancer.
Patients and methods: Two hundred patients from 15 institutions in four countries were randomly assigned to receive a 5-day course of chronomodulated 5-FU and LV (700 and 300 mg/m(2)/d, respectively; peak delivery rate at 0400 hours) with or without l-OHP on the first day of each course (125 mg/m(2), as a 6-hour infusion). Each course was repeated every 21 days. Response was assessed by extramural review of computed tomography scans.
Results: Grade 3 to 4 toxicity from 5-FU-LV occurred in </= 5% of the patients (</= 1% of the courses). Grade 3 to 4 diarrhea occurred in 43% of the patients given l-OHP (10% of the courses), and less than 2% of the patients had severe hematotoxicity. Thirteen percent of the patients had moderate functional impairment from peripheral sensory neuropathy. Sixteen percent of the patients receiving 5-FU-LV had an objective response (95% confidence interval [CI], 9% to 24%), compared with 53% of those receiving additional l-OHP (95% CI, 42% to 63%) (P <. 001). The median progression-free survival time was 6.1 months with 5-FU-LV (range, 4.1 to 7.4 months) and 8.7 months (7.4 to 9.2 months) with l-OHP and 5-FU-LV (P =.048). Median survival times were 19.9 and 19.4 months, respectively.
Conclusion: By chronomodulating 5-FU-LV, we were able to add l-OHP without compromising dose-intensities. l-OHP significantly improved the antitumor efficacy of this regimen.
Similar articles
- Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Lévi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, et al. Lévi FA, et al. J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17. doi: 10.1093/jnci/86.21.1608. J Natl Cancer Inst. 1994. PMID: 7932825 Clinical Trial. - A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
Lévi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C. Lévi F, et al. Cancer. 1999 Jun 15;85(12):2532-40. doi: 10.1002/(sici)1097-0142(19990615)85:12<2532::aid-cncr7>3.0.co;2-1. Cancer. 1999. PMID: 10375099 Clinical Trial. - Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmeier U, Atanackovic D, Nierhaus A, Hossfeld DK. Hegewisch-Becker S, et al. Ann Oncol. 2002 Aug;13(8):1197-204. doi: 10.1093/annonc/mdf216. Ann Oncol. 2002. PMID: 12181242 Clinical Trial. - [The role of oxaliplatin in the therapy for advanced colorectal carcinoma].
Nehls O, Porschen R, Gregor M, Klump B. Nehls O, et al. Z Gastroenterol. 2001 Dec;39(12):1033-47. doi: 10.1055/s-2001-19029. Z Gastroenterol. 2001. PMID: 11753789 Review. German. - A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
Beijers AJ, Mols F, Vreugdenhil G. Beijers AJ, et al. Support Care Cancer. 2014 Jul;22(7):1999-2007. doi: 10.1007/s00520-014-2242-z. Epub 2014 Apr 13. Support Care Cancer. 2014. PMID: 24728618 Review.
Cited by
- Overcoming Therapy Resistance in Colorectal Cancer: Targeting the Rac1 Signaling Pathway as a Potential Therapeutic Approach.
Anselmino LE, Malizia F, Avila A, Cesatti Laluce N, Mamberto M, Zanotti LC, Farré C, Sauzeau V, Menacho Márquez M. Anselmino LE, et al. Cells. 2024 Oct 26;13(21):1776. doi: 10.3390/cells13211776. Cells. 2024. PMID: 39513883 Free PMC article. - An RNA damage response network mediates the lethality of 5-FU in colorectal cancer.
Chen JK, Merrick KA, Kong YW, Izrael-Tomasevic A, Eng G, Handly ED, Patterson JC, Cannell IG, Suarez-Lopez L, Hosios AM, Dinh A, Kirkpatrick DS, Yu K, Rose CM, Hernandez JM, Hwangbo H, Palmer AC, Vander Heiden MG, Yilmaz ÖH, Yaffe MB. Chen JK, et al. Cell Rep Med. 2024 Oct 15;5(10):101778. doi: 10.1016/j.xcrm.2024.101778. Epub 2024 Oct 7. Cell Rep Med. 2024. PMID: 39378883 Free PMC article. - Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.
Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Yousef M, et al. JAMA Oncol. 2024 Sep 12:e243666. doi: 10.1001/jamaoncol.2024.3666. Online ahead of print. JAMA Oncol. 2024. PMID: 39264607 - Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis.
Keshavarzi F, Salari N, Jambarsang S, Mohammad Tabatabaei S, Shahsavari S, Fournier AJ. Keshavarzi F, et al. Heliyon. 2024 Aug 16;10(16):e36464. doi: 10.1016/j.heliyon.2024.e36464. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39253267 Free PMC article. - Journey through the Decades: The Evolution in Treatment and Shared Decision Making for Locally Advanced Rectal Cancer.
Gaetani RS, Ladin K, Abelson JS. Gaetani RS, et al. Cancers (Basel). 2024 Aug 9;16(16):2807. doi: 10.3390/cancers16162807. Cancers (Basel). 2024. PMID: 39199579 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical